Detailed Narrative
H1 FY26 Financial Performance
Influx Healthtech delivered a strong H1 FY26, with revenue from operations reaching INR 66.8 crores, marking a 39% year-on-year growth. EBITDA surged by 61% year-on-year to INR 14.7 crores, with margins expanding by 302 basis points to 22.0%. Net profit after tax (PAT) also saw robust growth, increasing by 78% year-on-year to INR 10 crores, and PAT margins improved by 329 basis points to 15.0%. The company maintains a healthy financial position with a cash surplus of INR 36.6 crores as of September 30, 2025.
Capacity Expansion and Operational Upgrades
The company undertook several capacity expansion and operational upgrade initiatives during H1 FY26, entirely funded through internal approvals. Key expansions include tablet manufacturing capacity to 10,000-15,000 bottles per day with an investment of INR 60 lakhs, and a new high-speed capsule manufacturing line capable of 1,22,000 capsules per hour for INR 34.5 lakhs. Additionally, liquid production lines were added, and sachet production capacity increased to 32,000 per shift with a total investment of INR 1.91 crores. All these projects are now fully operational, enhancing production capabilities.
IPO Proceeds Utilization and New Facility Development
Influx Healthtech has deployed INR 4.1 crores of its IPO proceeds towards capital expenditure, with INR 33.6 crores remaining in the bank for future investments. The company plans to utilize the remaining IPO funds to build a state-of-the-art nutraceutical and veterinary plant, with an estimated capex of INR 20-23 crores for nutra and INR 11 crores for veterinary. The target for this new facility to be in place is H1 FY27, though there has been a 1-1.5 month delay due to rains. Approximately INR 5-6 crores is planned for H2 FY26 for specific machinery like a retort plant and veterinary high-speed machines.
Segmental Growth and Diversification Strategy
While nutraceuticals continue to be the largest segment, contributing INR 60.1 crores (36% YoY growth), Influx Healthtech is actively diversifying its revenue streams. The cosmetics segment grew significantly by 59% YoY to INR 3.4 crores, and ayurvedic products saw a substantial increase of 112% YoY to INR 2.7 crores. The veterinary and home care segment also reported a 20% YoY increase, reaching INR 0.6 crores. The company's strategy is to focus on all segments to reduce dependence on nutraceuticals, with cosmetics and veterinary expected to offer better margins as they scale.
New Market Entry and International Expansion
The company is set to enter the beverage market with a new line capable of producing 10,000 bottles per hour, focusing on nutritional ready-to-drink (RTD) products. This initiative aims to tap into a new customer base and explore new market opportunities. Influx Healthtech is also expanding its global footprint, having secured FSSC 22000 certification from NSF International and US FDA registration, which opens doors to US and European markets. They are actively pursuing Tanzania approval, with an audit scheduled for December 11, 2025, to strengthen their presence in the African market.
Working Capital Management and Client Dynamics
Influx Healthtech operates as a debt-free company with no short-term borrowings. Management addressed concerns regarding high debtor days (113 days in March '25), explaining it is a strategic arrangement with a major client, Novus Life Sciences, who supplies raw materials and is paid upon utilization. This unique model helps manage working capital efficiently by reducing the need for external funding. The company is continuously working to further improve its payment and receivable cycles.